New Oral Anti-Coagulant (NOAC) Reversal Agents
Did you know that there is a universal reversal agent currently available for all clotting medications? The minefield of new oral anti-coagulant medications (NOACs) and their reversal agents can be confusing to try and navigate, not to mention trying to keep up with the latest evidence and developments. In this succinct talk, Dr Ali Bazargan presents an informative and easy-to-understand overview of these reversal agents and their risks and benefits. The only question remaining is, which one is best for your patient?
Dr Bazargan is a Haematology Consultant at St Vincent’s Hospital. He has broad expertise across the field of benign and malignant haematology, with a special emphasis on clotting/bleeding disorders, lymphomas, myelodysplastic syndrome, myeloproliferative disorders and FBE abnormalities. Dr Bazargan obtained his MD degree in 1992 and carried out his basic & advanced physician and haematology training at Monash Medical Centre, St Vincent’s Hospital and Peter MacCallum Cancer Centre. He is actively involved in clinical trials in a wide range of haematological malignancies as principal investigator or associate investigator at St Vincent’s Public Hospital. As a member of the Haematology Society of Australia & New Zealand, American Society of Haematology, Australasian Leukaemia & Lymphoma Group and European Haematology Association, Dr Bazargan is committed to providing individualized clinical care for patients with blood disorders and is well known for his dedication and compassion in achieving the best possible outcome for his patients.